[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11202004116QA - T cell manufacturing compositions and methods - Google Patents

T cell manufacturing compositions and methods

Info

Publication number
SG11202004116QA
SG11202004116QA SG11202004116QA SG11202004116QA SG11202004116QA SG 11202004116Q A SG11202004116Q A SG 11202004116QA SG 11202004116Q A SG11202004116Q A SG 11202004116QA SG 11202004116Q A SG11202004116Q A SG 11202004116QA SG 11202004116Q A SG11202004116Q A SG 11202004116QA
Authority
SG
Singapore
Prior art keywords
methods
cell manufacturing
manufacturing compositions
compositions
cell
Prior art date
Application number
SG11202004116QA
Inventor
Buuren Marit M Van
Divya Reddy Lenkala
Den Berg Joost Huibert Van
Jessica Kohler
Matthew Goldstein
Ed Fritsch
Renate Deboer
Ton Schumacher
Noor Bakker
Original Assignee
Biontech Us Inc
Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Us Inc, Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis filed Critical Biontech Us Inc
Publication of SG11202004116QA publication Critical patent/SG11202004116QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SG11202004116QA 2017-11-08 2018-11-08 T cell manufacturing compositions and methods SG11202004116QA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762583229P 2017-11-08 2017-11-08
US201762588590P 2017-11-20 2017-11-20
US201862618445P 2018-01-17 2018-01-17
US201862737625P 2018-09-27 2018-09-27
PCT/US2018/059896 WO2019094642A1 (en) 2017-11-08 2018-11-08 T cell manufacturing compositions and methods

Publications (1)

Publication Number Publication Date
SG11202004116QA true SG11202004116QA (en) 2020-06-29

Family

ID=66438061

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004116QA SG11202004116QA (en) 2017-11-08 2018-11-08 T cell manufacturing compositions and methods

Country Status (9)

Country Link
US (2) US11162072B2 (en)
EP (1) EP3706784A4 (en)
JP (3) JP7054418B2 (en)
KR (2) KR20230008254A (en)
CN (1) CN111867618A (en)
BR (1) BR112020008927A2 (en)
CA (1) CA3081840A1 (en)
SG (1) SG11202004116QA (en)
WO (1) WO2019094642A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202004116QA (en) 2017-11-08 2020-06-29 Biontech Us Inc T cell manufacturing compositions and methods
EP3810180A4 (en) * 2018-06-19 2022-03-30 BioNTech US Inc. Neoantigens and uses thereof
WO2020205778A1 (en) 2019-03-30 2020-10-08 Biontech Us Inc. Compositions and methods for preparing t cell compositions and uses thereof
TW202248419A (en) * 2019-05-08 2022-12-16 美商百歐恩泰美國公司 T cell manufacturing compositions and methods
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
CN110514845B (en) * 2019-08-22 2022-09-27 深圳新合睿恩生物医疗科技有限公司 Detection method and detection platform for immunogenicity of tumor neoantigen
US20230032934A1 (en) * 2019-11-27 2023-02-02 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
KR20220116475A (en) 2019-12-12 2022-08-23 아킬레스 테라퓨틱스 유케이 리미티드 Methods for obtaining nucleic acids for sequencing
GB201918290D0 (en) 2019-12-12 2020-01-29 Achilles Therapeutics Ltd Method
JP2023524435A (en) 2020-04-28 2023-06-12 アキレス セラピューティクス ユーケー リミテッド T cell therapy
EP4196135A4 (en) * 2020-08-13 2024-08-21 Biontech Us Inc T cell manufacturing compositions and methods
CN116507354A (en) 2020-08-13 2023-07-28 百欧恩泰美国公司 Ras novel antigen and use thereof
CA3200061A1 (en) * 2020-11-25 2022-06-02 Alfred E. Slanetz Antigen specific t cells and methods of making and using same
AU2021400424A1 (en) 2020-12-14 2023-07-06 Biontech Us Inc. Tissue-specific antigens for cancer immunotherapy
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
WO2022214835A1 (en) 2021-04-09 2022-10-13 Achilles Therapeutics Uk Limited Batch release assay for pharmaceutical products relating to t cell therapies
IL312121A (en) * 2021-10-15 2024-06-01 Biontech Us Inc T cell manufacturing compositions and methods
GB202210006D0 (en) 2022-07-07 2022-08-24 Achilles Therapeutics Uk Ltd Analysis of T cell samples
WO2024190864A1 (en) * 2023-03-15 2024-09-19 株式会社ガイアバイオメディシン Solution for suspending cells, and use of same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
JP3649335B2 (en) 1992-04-01 2005-05-18 ザ ロックフェラー ユニバーシティー Method for in vitro expansion of dendritic cell precursors and their use in immunogen production
NZ255683A (en) 1992-08-07 1996-08-27 Cytel Corp Immunogenic composition comprising a 9-10 aa residue peptide having a hla-a3.2, hla-a1, hla-a11 or hla-a24.1 binding motif
AU6359494A (en) 1993-03-05 1994-09-26 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO2005030196A2 (en) * 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using il-21
WO2006015497A1 (en) 2004-08-13 2006-02-16 Val-Chum, S.E.C. Methods of use of a dkk1 protein, immunogenic polypeptides thereof, nucleic acid encoding the dkk1 protein or polypeptides, or ligands thereof for detecting tumors; and for eliciting immune response against tumors
WO2006110582A1 (en) * 2005-04-08 2006-10-19 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
US9809797B2 (en) * 2007-10-03 2017-11-07 National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
KR20160101073A (en) 2013-12-20 2016-08-24 더 브로드 인스티튜트, 인코퍼레이티드 Combination therapy with neoantigen vaccine
EP3134512B1 (en) 2014-04-24 2019-01-02 Miltenyi Biotec GmbH Method for automated generation of genetically modified t cells
CN103923880B (en) 2014-05-08 2016-03-30 成都百赛泰科生物科技有限公司 The CTL preparation method of a kind of high efficiently multiplying, target killing tumour
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
SG11202004116QA (en) 2017-11-08 2020-06-29 Biontech Us Inc T cell manufacturing compositions and methods

Also Published As

Publication number Publication date
JP2021502414A (en) 2021-01-28
EP3706784A1 (en) 2020-09-16
JP7420856B2 (en) 2024-01-23
KR102484433B1 (en) 2023-01-03
EP3706784A4 (en) 2021-12-01
BR112020008927A2 (en) 2020-10-20
CA3081840A1 (en) 2019-05-16
JP7054418B2 (en) 2022-04-13
KR20230008254A (en) 2023-01-13
RU2020118338A3 (en) 2022-03-31
US20220177840A1 (en) 2022-06-09
CN111867618A (en) 2020-10-30
WO2019094642A8 (en) 2019-11-28
US20200165567A1 (en) 2020-05-28
RU2020118338A (en) 2021-12-08
JP2022106722A (en) 2022-07-20
WO2019094642A1 (en) 2019-05-16
US11162072B2 (en) 2021-11-02
JP2024041873A (en) 2024-03-27
KR20200109301A (en) 2020-09-22

Similar Documents

Publication Publication Date Title
SG11202004116QA (en) T cell manufacturing compositions and methods
HK1250481A1 (en) Modified t cells and methods of making and using the same
IL268970A (en) Novel compositions and methods
IL259586B (en) Genetically modified stem cells and uses thereof
IL269334A (en) Improved t cell compositions and methods
SG11202005062SA (en) Electrochemical methods, devices and compositions
GB2546350B (en) Compositions and methods
IL287874A (en) T cell manufacturing compositions and methods
HUE065174T2 (en) Hla-based methods and compositions and uses thereof
IL273915A (en) Cell
GB201807325D0 (en) Compositions and methods
GB201718876D0 (en) Antithrombin-heparin compositions and methods
SG11202004253QA (en) Oil-and-fat composition and manufacturing method thereof
GB202201859D0 (en) Novel methods and compositions
IL255480B (en) Compositions comprising mesenchymal stem cells and uses thereof
GB201707779D0 (en) Cell
ZA202004533B (en) Skin-brightening compositions and methods
IL273247A (en) Novel cell line and uses thereof
GB201705626D0 (en) Compositions and methods
ZA201807665B (en) Methods and compositions
GB201715820D0 (en) Compositions and methods
GB201512996D0 (en) Compositions and methods
GB201703975D0 (en) Composition and methods
GB201514413D0 (en) Compositions and methods
ZA201807782B (en) Methods and compositions